VAXCYTE INC's ticker is PCVX and the CUSIP is 92243G108. A total of 127 filers reported holding VAXCYTE INC in Q3 2022. The put-call ratio across all filers is 0.98 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $25,472,157 | -10.7% | 499,650 | -12.5% | 2.35% | -25.9% |
| Q2 2023 | $28,528,225 | +100.2% | 571,250 | +50.2% | 3.17% | +114.8% |
| Q1 2023 | $14,251,770 | -23.4% | 380,250 | -2.0% | 1.48% | -44.7% |
| Q4 2022 | $18,602,203 | +130.9% | 387,950 | +15.6% | 2.67% | +143.7% |
| Q3 2022 | $8,056,000 | -0.1% | 335,650 | -9.4% | 1.10% | -13.0% |
| Q2 2022 | $8,065,000 | +1.7% | 370,650 | +12.9% | 1.26% | +23.0% |
| Q1 2022 | $7,930,000 | +13.1% | 328,350 | +11.4% | 1.02% | +45.7% |
| Q4 2021 | $7,012,000 | -22.3% | 294,750 | -17.1% | 0.70% | -50.1% |
| Q3 2021 | $9,023,000 | +6.7% | 355,650 | -5.3% | 1.41% | +8.2% |
| Q2 2021 | $8,456,000 | +45.8% | 375,650 | +27.9% | 1.30% | +24.4% |
| Q1 2021 | $5,800,000 | – | 293,650 | – | 1.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Abingworth LLP | 4,168,718 | $90,711,000 | 29.04% |
| Medicxi Ventures Management (Jersey) Ltd | 3,774,956 | $82,142,000 | 17.06% |
| Pivotal bioVenture Partners Investment Advisor LLC | 832,166 | $18,108,000 | 9.12% |
| GREAT POINT PARTNERS LLC | 985,153 | $21,437,000 | 5.14% |
| Kynam Capital Management, LP | 723,781 | $15,749,000 | 4.02% |
| Ghost Tree Capital, LLC | 325,000 | $7,072,000 | 3.68% |
| Frazier Life Sciences Management, L.P. | 1,787,405 | $38,894,000 | 3.67% |
| RA Capital Management | 4,581,203 | $99,687,000 | 2.66% |
| Opaleye Management Inc. | 190,000 | $4,134,000 | 1.86% |
| Soleus Capital Management, L.P. | 370,650 | $8,065,000 | 1.26% |